Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications

Angiogenesis

Volumn 1, Issue 1, 1997, Pages 71-83

  Toi, Masakazu ^a   Gion, Massimo ^b   Biganzoli, Elia ^c   Dittadi, Ruggero ^b   Boracchi, Patrizia ^c   Miceli, Rosalba ^c   Meli, Salvatore ^d   Mori, Kazushige ^e   Tominaga, Takeshi ^a   Gasparini, Giampietro ^f  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b Regional Medical Centre   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d St Bortolo Medical Centre   (Italy)

^e NIPPON ROCHE RESEARCH CENTER   (Japan)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Breast cancer; Prognosis

Indexed keywords

EID: 0002722679     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018305132489     Document Type: Article

References (42)

1. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer. Update of the biological background and overview of the Vicenza studies. Eur J Cancer 1996; 32A, 2485-93.
2. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A, 2451-2460.
3. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T. Clinical significance of the determination of angiogenic factors. Eur J Cancer 1996; 32A, 2513-2519.
4. Page DL, Jensen RA. Angiogenesis in human breast carcinoma: what is the question? Human Pathol 1995; 26, 1173-1174.
5. Simpson JF, Battifora H. Angiogenesis as a prognostic factor in breast cancer: can we count on it? Appl Immunohistochem 1995; 3, 73-74.
6. Walker RA. Angiogenesis and breast cancer prognosis - a continuous issue. J Pathol 1996; 180, 6-7.
7. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A, 2474-2484.
8. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis on vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77, 1101-1106.
9. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89, 139-147.
10. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86, 356-361.
11. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995; 1, 1031-1034.
12. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in sera of normal controls and cancer patients. Clin Cancer Res 1996; 2, 821-826.
13. Gasparini G. Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer 1996; 32A, 2379-2385.
14. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69, 508-517.
15. Koolwijk P, van Erck MGM, de Vree WJA, et al. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132, 1177-1188.
16. Bouck N. p53 and angiogenesis. Biochim Biophys Acta 1996; 1287, 63-66.
17. Gasparini G, Harris AL. p53 and angiogenesis in neoplasia. In: Klijn JGM (ed.), ESO Scientific Updates. Vol. 1. Prognostic and Predictive value of p53. Amsterdam: Elsevier 1997; 115-130.
18. Gasparini G. Angiogenesis in endocrine-related tumours. Endocr-Rel Cancer 1997; 4, in press.
19. Moghaddam A, Zhang H-T, Fan T-PD, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92, 998-1002.
20. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88, 1442-1445.
21. Ravdin PM, Tandon AK, Allred DC, et al. Cathepsin-D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 1994; 12, 467-474.
22. Gion M, Mione R, Dittadi R, et al. Relationship between Cathepsin-D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 1995; 31, 671-677.
23. Revision of the standards for the assessment of hormone receptors in human breast cancer. Report of the second EORTC Workshop, held on 16-17 March, 1979 at The Netherlands Cancer Institute. Eur J Cancer 1980; 16, 1513-1515.
24. Nishida M, Hino A, Mori K, et al. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996; 11, 1407-1411.
25. Borg A, Lennerstrand J, Stenmark-Askmalm M, et al. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 1995; 71, 1013-1017.
26. Marubini E, Valsecchi MG (Eds). Analysing Survival Data from Clinical Trials and Observational Studies. Chichester: John Wiley: 1995.
27. Durrleman S and Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8, 551-561.
28. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15, 361-387.
29. Akaike H. Information theory and an extension of the Maximum Likelihood Principle. In: Patrov BN, Csaki F (eds), Proc 2nd Int Symp on Information Theory. Budapest: Akademia Kiedo 1973.
30. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas. Int J Cancer (Pred Oncol) 1996; 69, 205-211.
31. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333, 1757-1763.
32. Hanahan D, Folkman J. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86, 353-364.
33. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93, 14765-14770.
34. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2, 1096-1103.
35. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic acitivity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338, 557-562.
36. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S-I. Angiogenic factor. Nature 1992; 356, 668.
37. Haraguchi M, Kazutaka M, Uemura K, et al. Angiogenic activity of enzymes. Nature 1994; 368, 198.
38. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995; 86, 2488-2493.
39. Patterson A, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995; 72, 669-675.
40. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann Oncol 1996; 7, 441-444.
41. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors. Nat Med 1996; 2, 689-692.
42. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32A, 2413-2422.